ARVO: Two-Year Safety Equal in AMD Drug Trial
FORT LAUDERDALE (MedPage Today) -- Preliminary two-year safety data from the landmark CATT trial of ranibizumab (Lucentis) and bevacizumab (Avastin) for macular degeneration partially reversed conclusions from the one-year results reported last week, study leaders said in an oral presentation Sunday.